aleniglipron vs elecoglipron

NCT06703021 · Phase 2 · completed

The study was randomized, triple-blind, and placebo-controlled, with 85 participants. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Registered primary outcomes are safety measures; the weight-loss figures are the trial's prespecified efficacy readout, reported in the sponsor's topline press release and not yet peer reviewed. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

NCT06579092 · Phase 2 · completed

This randomised, triple-blind, placebo-controlled trial in 310 adults living with obesity or overweight reported a 10.5% reduction in body weight on elecoglipron 75 mg against 0.6% on placebo at 26 weeks. Percent weight change is the measure regulators accept as the primary efficacy endpoint in obesity.

NCT05762471 · Phase 1/2 · completed

The study randomized 142 participants to GSBR-1290 or placebo with participants, care providers, and investigators masked. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Registered primary endpoint is safety/tolerability; the weight results are the phase 2a obesity cohort's efficacy readout from the sponsor's SEC-filed topline release, not yet peer reviewed.

NCT06579105 · Phase 2 · completed

Participants receiving AZD5004 or placebo were randomized and kept blinded to treatment; a semaglutide comparator arm was open-label but was not part of the primary comparison. The highest dose produced a substantially larger drop in HbA1c than placebo, meeting the trial's main goal.